Information and Resources
Stereotactic body radiation therapy or SBRT (sometimes referred to as Cyberknife or SHARP) has had excellent 7-year outcomes in an update of the consortium study, including data from 10 single-institution trials and two multi-institutional trials. Get the details HERE.
Men who are initially diagnosed with intermediate-risk prostate cancer may or may not be good candidates for Active Surveillance. This excellent article begins to provide a basis for making that determination. You can read the article by clicking HERE.
Moderately hypofractionated IMRT (radiation therapy delivered in 20 to 26 treatments instead of the conventional 40-44 treatments) has received strong endorsement from all of the major US organizations of physicians who treat prostate cancer. Read more about this significant new guideline here.
Scientists at Cedars-Sinai have discovered how prostate cancer can sometimes withstand and outwit a standard hormone therapy, causing the cancer to spread. Their findings also point to a simple blood test that may help doctors predict when this type of hormone therapy resistance will occur. Learn more about these interesting findings by clicking HERE.